

EXHIBIT B

GENEVANT

October 12, 2021

BY FEDERAL EXPRESS

Michael P. Bauer, Ph.D.
Assistant General Counsel
Pfizer, Inc.
235 East 42nd Street
New York, New York 10017


Re: Arbutus/Genevant LNP Technology and Intellectual Property

Dear Mr. Bauer:

Thank you for your October 7, 2021, email to Pete Zorn informing Genevant that BioNTech will be handling further discussions regarding a potential license relating to COVID-19 vaccines. We look forward to hearing from BioNTech.

In the meantime, we believe, and notify Pfizer and BioNTech under 35 U.S.C. § 287(a), that the manufacture, importation, offer for sale, sale, and/or use of the Pfizer-BioNTech COVID-19 vaccine Comirnaty® may infringe Arbutus U.S. Patent No. 11,141,378, in addition to at least the Arbutus patents that were identified in our November 23, 2020 letter.

Sincerely,



Markus Rohrwild
Managing Director
Genevant Sciences GmbH
Viaduktstrasse 8, 4051
Basel, Switzerland



William H. Collier
President and Chief Executive Officer
Arbutus Biopharma Corporation
701 Veterans Circle
Warminster, Pennsylvania 18974 USA

Cc: Ugur Sahin
Chief Executive Officer
BioNTech SE
An der Goldgrube 12
D-5131 Mainz Germany

Albert Bourla, DVM, Ph.D.
Chairman and Chief Executive Officer
Pfizer, Inc.
235 East 42nd Street
New York, New York 10017 USA

Sierk Poetting
Chief Financial Officer and Chief
Operating Officer
BioNTech SE
An der Goldgrube 12
D-55131 Mainz Germany

Doug Lankler, Esq.
Executive Vice President, General Counsel
Pfizer, Inc.
235 East 42nd Street
New York, New York 10017 USA

General Counsel
BioNTech US Inc.
40 Erie Street, Suite 110
Cambridge, MA 02139 USA

10298-00001/12998850.1